Zacks: Analysts Expect Strongbridge Biopharma PLC (SBBP) Will Post Quarterly Sales of $1.97 Million
Equities analysts predict that Strongbridge Biopharma PLC (NASDAQ:SBBP) will post $1.97 million in sales for the current quarter, Zacks reports. Three analysts have issued estimates for Strongbridge Biopharma PLC’s earnings, with estimates ranging from $1.20 million to $2.96 million. The firm is scheduled to announce its next earnings results on Friday, December 22nd.
On average, analysts expect that Strongbridge Biopharma PLC will report full-year sales of $1.97 million for the current year, with estimates ranging from $4.64 million to $8.11 million. For the next year, analysts forecast that the firm will report sales of $13.87 million per share, with estimates ranging from $9.39 million to $21.40 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that cover Strongbridge Biopharma PLC.
Strongbridge Biopharma PLC (NASDAQ:SBBP) last announced its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.34) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.34). The company had revenue of $1.53 million for the quarter, compared to analysts’ expectations of $0.84 million.
SBBP has been the subject of several recent research reports. Zacks Investment Research upgraded shares of Strongbridge Biopharma PLC from a “hold” rating to a “buy” rating and set a $7.75 target price for the company in a research note on Wednesday, July 19th. HC Wainwright restated a “buy” rating on shares of Strongbridge Biopharma PLC in a research report on Wednesday, May 17th. ValuEngine upgraded shares of Strongbridge Biopharma PLC from a “sell” rating to a “hold” rating in a research report on Tuesday, June 27th. Finally, Oppenheimer Holdings, Inc. began coverage on shares of Strongbridge Biopharma PLC in a research report on Thursday, August 10th. They set an “outperform” rating and a $12.00 price target for the company. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $11.94.
Strongbridge Biopharma PLC (SBBP) opened at 6.50 on Wednesday. The firm’s market capitalization is $229.68 million. Strongbridge Biopharma PLC has a 52-week low of $2.00 and a 52-week high of $8.85. The company’s 50-day moving average is $6.97 and its 200-day moving average is $4.97.
Large investors have recently modified their holdings of the stock. California State Teachers Retirement System acquired a new stake in shares of Strongbridge Biopharma PLC during the second quarter worth $277,000. State Street Corp acquired a new stake in shares of Strongbridge Biopharma PLC during the second quarter worth $443,000. Nexthera Capital LP acquired a new stake in shares of Strongbridge Biopharma PLC during the second quarter worth $477,000. Vanguard Group Inc. acquired a new stake in shares of Strongbridge Biopharma PLC during the second quarter worth $474,000. Finally, Northern Trust Corp acquired a new stake in shares of Strongbridge Biopharma PLC during the second quarter worth $1,462,000. 63.65% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY WARNING: This news story was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of international trademark and copyright laws. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/08/30/zacks-analysts-expect-strongbridge-biopharma-plc-sbbp-will-post-quarterly-sales-of-1-97-million.html.
Strongbridge Biopharma PLC Company Profile
Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Strongbridge Biopharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma PLC and related stocks with our FREE daily email newsletter.